RhumbLine Advisers’s Zimmer Biomet ZBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$43.8M Buy
484,909
+19,588
+4% +$1.8M 0.04% 395
2025
Q4
$41.8M Buy
465,321
+7,057
+2% +$669K 0.03% 423
2025
Q3
$45.1M Buy
458,264
+2,059
+0.5% +$204K 0.04% 402
2025
Q2
$41.6M Buy
456,205
+29,678
+7% +$2.87M 0.04% 420
2025
Q1
$48.3M Buy
426,527
+22,889
+6% +$2.45M 0.05% 351
2024
Q4
$42.6M Sell
403,638
-8,413
-2% -$903K 0.04% 386
2024
Q3
$44.5M Sell
412,051
-3,728
-0.9% -$407K 0.04% 374
2024
Q2
$45.1M Sell
415,779
-15,363
-4% -$1.81M 0.04% 358
2024
Q1
$56.9M Buy
431,142
+8,355
+2% +$1.04M 0.05% 297
2023
Q4
$51.5M Sell
422,787
-3,194
-0.7% -$356K 0.05% 301
2023
Q3
$47.8M Sell
425,981
-8,871
-2% -$1.13M 0.06% 296
2023
Q2
$63.3M Sell
434,852
-1,270
-0.3% -$173K 0.07% 247
2023
Q1
$56.3M Buy
436,122
+10,707
+3% +$1.34M 0.07% 259
2022
Q4
$54.2M Buy
425,415
+14,642
+4% +$1.7M 0.07% 254
2022
Q3
$42.9M Buy
410,773
+16,358
+4% +$1.8M 0.06% 277
2022
Q2
$41.4M Buy
394,415
+19,413
+5% +$2.3M 0.06% 284
2022
Q1
$48M Sell
375,002
-65
-0% -$7.83K 0.06% 276
2021
Q4
$46.3M Buy
375,067
+7,446
+2% +$975K 0.06% 297
2021
Q3
$52.2M Sell
367,621
-2,803
-0.8% -$412K 0.07% 237
2021
Q2
$57.8M Sell
370,424
-3,884
-1% -$629K 0.08% 230
2021
Q1
$58.2M Sell
374,308
-22,132
-6% -$3.43M 0.08% 221
2020
Q4
$59.3M Buy
396,440
+6,971
+2% +$985K 0.08% 214
2020
Q3
$51.5M Sell
389,469
-1,814
-0.5% -$237K 0.08% 221
2020
Q2
$45.3M Sell
391,283
-7,887
-2% -$909K 0.08% 224
2020
Q1
$39.2M Buy
399,170
+29,125
+8% +$3.82M 0.08% 219
2019
Q4
$53.8M Buy
370,045
+11,813
+3% +$1.63M 0.09% 209
2019
Q3
$47.7M Buy
358,232
+6,948
+2% +$898K 0.09% 214
2019
Q2
$40.2M Buy
351,284
+2,322
+0.7% +$272K 0.08% 234
2019
Q1
$43.3M Sell
348,962
-32,136
-8% -$3.65M 0.08% 211
2018
Q4
$38.4M Buy
381,098
+1,134
+0.3% +$128K 0.08% 221
2018
Q3
$48.5M Sell
379,964
-9,282
-2% -$1.1M 0.09% 204
2018
Q2
$42.1M Sell
389,246
-5,083
-1% -$553K 0.08% 229
2018
Q1
$41.7M Sell
394,329
-1,655
-0.4% -$192K 0.09% 232
2017
Q4
$46.4M Buy
395,984
+8,669
+2% +$980K 0.09% 216
2017
Q3
$44M Buy
387,315
+10,517
+3% +$1.21M 0.1% 219
2017
Q2
$47M Buy
376,798
+1,637
+0.4% +$194K 0.11% 201
2017
Q1
$44.5M Buy
375,161
+8,978
+2% +$1.02M 0.1% 208
2016
Q4
$36.7M Buy
366,183
+22,266
+6% +$2.39M 0.09% 227
2016
Q3
$43.4M Buy
343,917
+26,999
+9% +$3.34M 0.12% 179
2016
Q2
$37M Buy
316,918
+52,803
+20% +$5.98M 0.11% 192
2016
Q1
$27.3M Buy
264,115
+17,899
+7% +$1.73M 0.08% 242
2015
Q4
$24.5M Sell
246,216
-63
-0% -$6.16K 0.08% 251
2015
Q3
$22.5M Buy
246,279
+6,535
+3% +$655K 0.08% 262
2015
Q2
$25.4M Buy
239,744
+10,889
+5% +$1.2M 0.08% 247
2015
Q1
$26.1M Sell
228,855
-14,187
-6% -$1.62M 0.08% 241
2014
Q4
$26.8M Buy
243,042
+9,503
+4% +$1M 0.08% 239
2014
Q3
$22.8M Sell
233,539
-6,524
-3% -$642K 0.07% 255
2014
Q2
$24.2M Sell
240,063
-5,792
-2% -$565K 0.07% 254
2014
Q1
$22.6M Buy
245,855
+1,792
+0.7% +$165K 0.07% 272
2013
Q4
$22.1M Sell
244,063
-13,939
-5% -$1.21M 0.07% 278
2013
Q3
$20.6M Buy
258,002
+719
+0.3% +$56.6K 0.06% 297
2013
Q2
$18.7M Buy
+257,283
New +$19.2M 0.06% 302

Other funds holding ZBH

RhumbLine Advisers's ZBH Position: Q1 2026 in Review

RhumbLine Advisers increased its Zimmer Biomet (ZBH) stake by 4.2% in Q1 2026, buying an estimated $1.8M and bringing the position to 484,909 shares worth $43.8M. The position accounts for 0.04% of the portfolio, ranked #395.

RhumbLine Advisers first reported a position in ZBH in Q2 2013 and has held it in 52 quarters since. The position peaked at $63.3M in Q2 2023. 912 funds tracked by Wall St. Rank hold ZBH as of Q1 2026.

  • RhumbLine Advisers held 484,909 shares of Zimmer Biomet worth $43.8M as of Q1 2026.
  • RhumbLine Advisers bought 19,588 Zimmer Biomet shares in Q1 2026, an estimated $1.8M.
  • Zimmer Biomet made up 0.04% of RhumbLine Advisers's portfolio in Q1 2026, its #395 holding.
  • RhumbLine Advisers first reported a position in Zimmer Biomet in Q2 2013 and has held it in 52 quarters since.
  • RhumbLine Advisers's Zimmer Biomet position peaked at $63.3M in Q2 2023.
  • 912 funds tracked by Wall St. Rank held Zimmer Biomet as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.